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Abstract:To clarify the relationship between
the alterations of the levels of angiotensin
converting enzyme (ACE) and diabetic nephropathy, ACE activity in the lung, liver, kidney and serum were investigated in streptozotocin (STZ)-induced diabetic rats.
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The levels of serum ACE activity unchanged 3
days post STZ treatment but it was significantly an increase 12 and 30 days post
STZ treatment in diabetic rats (p<0.001).
Lung ACE activity was significantly incerased
at 12 and 30 days post STZ Treatment in diabetic rats (P<0.05 and P<0.005). There
was not showed an increase in the liver ACE
activity at 3 and 12 days in diabetic rats such
it was significantly elevated at 30 day in diabetic rats (P<0.05). Kidney ACE activity was
significantly elevated at 12 day post STZ

Introduction
Diabetes mellitus is associated with an increased of
hypertension and renal failure (1,2). Many abnormalities of diabetic state promote microvascular complications, including glomerulopathy. Prominent among
these are early hemodynamic maladaptations (systemic
and glomerular capillary hypertension), which have
been implicated as major risk factors for eventual diabetic glomerulopathy and alterations of renin angiotensin system (RA) (3). Hormonal modulation of
these hemodynamic changes in diabetes is complex (3).
Many investigators reported that changes in the RA
system and ACE activity may be linked to the onset of
microvascular in diabetes mellitus (4). Angiotensin corventing enzyme (ACE, EC. 3.4.15.1) is synthesized by
endothelial and epithelial cells of many tissues including lung, kidney, heart and blood vessels (5). Although the enzyme bound to pulmonary vascular bed
is considered to be responsible for conversion of circulating A I to A II, the presence of ACE can be easily

treatment in diabetic rats, whereas were not
occurred significantly an increase at 3 and 30
days in diabetic rats (p<0.05).
Histopathologic examination of the kidneys
showed that thickening of the glomerular
basement membrane, glomerular sclerosis,
tubular dilatation and “Capsular Cap” occurred in the kidneys of STZ-induced-diabetic
rats at 12 and 30 days.
In summary, it can be considered that high
serum, lung and kidney ACE activity levels
were related to with the complications in diabetic rats.
Key Words: Angiotensin Converting Enzyme,
Streptozotocin-Diabetes, Nephropathy.

detected in human or animal serum (6). ACE is a
large acidic glycoprotein metalloenzyme composed of a
single polypeptide chain that contains zinc molecule in
a 1:1 molar ratio (6,7). The carboxy terminal dipeptide His9-Leu 10 is then cleaved from A I by ACE to
form the active hormone, A II (7). A II is known as a
potent vasoconstrictor in human body. Increase in angiotensin II level may result in the elevation of systolic
and diastolic pressures (8).
The reasons of development of nephropathy in diabetics may be intrarenal or nonintrarenal (8). Although, the reasons of nephropathy in diabetics nephropathy are very complicated, the main factor is
increasement of peripheral vascular resistant. In these
cases; RA system can not work due to the barrier
present between juxtaglomerular apparatus and the
glomerular arterioles (9,10). The role of renin and aldosterone is to prevent hypertension getting worse
through decreasing the high levels of the blood potassium, (11,12).
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Increased vascular ACE concentration may contribute to vascular hypertrophy and diabetic vasculopathy
by increased local synthesis of angiotensin II (13).
Changes in serum levels of ACE have been associated
with many pathologic conditions of the lung and the
liver. In addition, it was reported by Liebermann et
all. That level of ACE was elevated in diabetic patients
and rats (14). Use of ACE inhibitors and metabolic
control of diabetes will likely alter the prognosis of
patients with diabetic nepropathy substantially (10).
The present study was designed to clarify the direct effect of diabetes on serum and tissue (lung, liver
and kidney) ACE activity in STZ-induced diabetic rats
(15).
Material and Method
Forty six male wistar strain rats (8-10 weeks and
180-220 gr. weights) were used in these experiments.
Diabetic rats were randomly divided into three groups
(Day 3, Day 12 and Day 30). Similarly, the control
rats were divided into three groups. Rats were permitted rat chow water ad libitum.
Induction and evaluation of diabetes
Experimental diabetes was induced by injecting intraperitoneal a single dose freshly prepared STZ (60
mg/kg) in 0.1 M citrate Phosphate buffer (pH=4,5).
Control rats received an equal volume/kg body weight
of buffer (16). STZ injected animals were considered
diabetic, if urinary glucose levels and tail vein glucose
levels of rats exceeds 250 mg/dl (16,17)
In study days (3,12 and 30 days) rats were lightly
ether anesthetized and laparotomized. The blood samples of diabetic and control rats were obtained by cardiac puncture. Blood samples were centrifuged 15 min
at 3000 rpm and serum were obtained. After blood
sampling the kidney, the lung and the liver were removed from each animal, washed in saline and frozen
at -20˚C to be stored for later use.
Biochemical Studies
Serum glucose levels were measured at the end of
each experiment using a spectrophotometric glucose
oxidase method with Technicon RA-XT autoanalyzer.
Serum was stored at-20 C˚ until assayed for glucose.

(St. Louis, MO, 63103 USA). The package included
procedural inserts, lyophilized reagent containing the
substrate 2-furanoacryloyl-L-phenylalanınyl-glycylglycıne
(FAPPG), normal and above controls, and a calibrator.
Reconstituted reagent was claimed to have 0..5 mmol/
L of FAPPG and a pH=8.2 ± 0.1. All analyses were
determined at 37 C˚ over an incubation time of 5 min
using the 340/380 nm filter of a spectrophotometer
(Schimadzu UV-1201).
Histopathologic Studies
In histopathologic studies, tissue was fixed 10 %
buffered formalin and embedded in paraffin. Three
micron sections were stained hematoxylin and eosin
for pathologic examination.
The homogenates of the lung, the liver and the
kidney were prepared in 10 mmol/L sodium phosphate
buffer (pH: 6) using a Potter Elvenjem homogenizer
at+4 C˚. Homogenates were centrifuged at+4 C˚ for
20 min at 10 000 rpm. The supernatant was used
for the measurement of ACE. Protein was determined
by the method of Lowry et all. (18-21).
Statistical Analysis
Results were reported as mean ± standard error
the mean. Differences in our findings between groups
were quantitated using a Mann Whitney U test, 2
tailed, with a 95 confidence interval (22,23).
Results
Levels of blood glucose
Diabetic rats showed a marked rise in blood glucose levels. Levels of blood glucose in STZ-induced diabetic rats was significantly elevated compared with the
controls in 3, 12 and 30 days post STZ treatment
(P<0.001) (Table 1).
Table 1.
Days
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3

12

30

136±3,8

138±4,7

140±3,8

(n:8)

(n:8)

(n:8)

398±8,2***

488±11,7***

658±29,6***

(n:8)

(n:7)

(n:7)

Glucose (mg/dl)
Control
Diabetes mellitus

Measurement of Serum and Tissue ACE Activity
A commercial kit for spectrophotometric determination of ACE, based on the method of Holmquist et all. (21) was a gift from Sigma Diagnostics.

Serum glucose levels 3-30 days post STZ treatment.
(Mann-Whitney U Test)

***P<0.001
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Levels of serum ACE activity
ACE activity was measured in serum 3-30 days
post STZ treatment. Serum ACE activity were unchanged 3 days post STZ treatment. This indicates
STZ has no direct immediate effect on ACE activity.
Serum ACE activity measured 12 days and 30 days
post STZ treatment, was showed an increase in diabetic rats relative to control groups (P<0.001) (Table
2, Fig. 1).
The lung ACE activity in STZ-induced rats was significantly difference elavated compared with to control
at 12 day (P<0.05), whereas on significantly difference in the lung ACE activity at 3 day in diabetic rats
(P<0.05). Lung ACE activity was decreased at 30 day
in diabetic rats (Table 3, Fig. 2).

Levels of blood urea and creatinine in STZ-induced
diabetic rats were showed a significantly increase at
12 days 30 days (p<0.005), whereas no significant
changes were found in 3 days. The blood electrolytes
changed lightly, too. As shown Table 6; the level of
sodium and potassium increased significantly at 12
days (P<0.005), while the levels of sodium and potassium reduced in 30 days post STZ treatment and it
was statistically significantly (P<0.005).
Table 2.

Serum ACE activity levels control and STZ-induced diabetic
rats at 3-30 days. (Mann-Whitney U Test)

Days

3

12

30

Serum Angiotensin Converting Enzyme (U/L)

Diabetes mellitus

60,00 40,00 -

*

12

30

activity

of

the

lung

Days

The level of ACE activity of the liver tissue (*P<0.05).

9,20 _ ACE
9,00 _
8,80 _
8,60 _
8,40 _
8,20 _
8,00 _
7,80 _
7,60 _
7,40 _
7,20

*
Control
DM

3

tissue
Figure 4.

12

_

Days

_

30

12

Figure 3.

_

nmolI HA/ mg protein

Control
DM

_

The level of ACE
(P*<0.05,**P<0.005).

Control
DM

3

**

_

Figure 2.

(n:7)

ACE

Days

*

3

(n:7)

30

12

The level of serum ACE activity 3-30 days post STZ or
citrate buffer injection (**P<0.005).

ACE
_
14,00
12,00 _
10,00 _
8,00 _
6,00 _
4,00 _
2,00 _
0,00

65,41±0,85 101,2±2,63**120,1±1,62**

_

Figure 1.

8,00 _
7,00 _
6,00 _
5,00 _
4,00 _
3,00 _
2,00 _
1,00 _
0,00

nmol HA/mg protein

3

(n:8)

**P<0.005

-

-

0,00

-

20,00 -

(n:8)

_

80,00 -

66,31±2,14

(n:8)

nmol HA/mg protein

**

100,00 U/L

Control
DM

**

65,41±1,42
(n:8)

ACE
140,00 120,00 -

64,9±1,01

_

As shown Table 5, the ACE activity in the kidney
was increased partially at 12 days (P>0.05), whereas
no significant changes in the ACE activity of kidney at
3 and 30 days in STZ-induced diabetic rats (Table 5,
Fig. 4).

Control

_

The liver ACE activity was not significantly differences at 3 and 12 days in diabetic rats but conversely
it was significantly elevated compared with to control
at 30 days (P>0.05) (Table 4, Fig. 3).

30

Days

The level of ACE activity of kidney tissue (P*<0.05).
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Table 3.

The level of ACE activity of lung tissue. (Mann-Whitney U
Test)

Days

3

12

30

Lung ACE Activity Levels (nmol HA / mg protein)
Control

11,28±0,61
(n:8)

Diabetes mellitus

11,85±0,58
(n:8)

11,82±2,18 10,92±1,65
(n:8)

(n:8)

12,80±1,27* 8,37±0,79**
(n:7)

(n:7)

*P<0.05, **P<0.005

Table 4.

The liver ACE activity in control and STZ-induced diabetic
rats at 3-30 days. (Mann-Whitney U Test)

Days
Control
Diabetes mellitus

3
12
30
Liver ACE Activity Level (nmol HA/ mg protein)
7,20±0,45
7,33±0,62
7,39±0,37
(n:8)
(n:8)
(n:8)
7,20±0,65
6,48±1,46
5,73±1,85*
(n:8)
(n:7)
(n:7)

*P<0.05

Table 5.

The kidney ACE activity in control and STZ-induced diabetic
rats at 3-30 days. (Mann-Whitney U Test)

Days
Control

Diabetes mellitus

3

12

30

8,12±2,1

8,25±0,94

8,11±1,22

(n:8)

(n:8)

(n:8)

8,25±0,37

9,11±2,35*

7,95±1,3

(n:8)

(n:7)

(n:7)

Histopathologic Results
The renal and pancreatic structural changes caused
by diabetes mellitus are examined at light microscopic
level using several histochemical techniques. In STZInduced diabetic rats showed that langerhans islets in
pancreatic gland were occurred damage, including acini
degradation and polymorfonuclear leucocyte (PNL) in
pancreatic endocrine gland in STZ-induced diabetic rats
at 3 days compared with to control. In addition, especially pancreatic islet cells showed that were occurred damage and decreasing in number (Fig. 5).
These findings continued more clear at 12 and 30
days in diabetic rats and evidence PNL and partially fibrosis were increased in diabetic rats.
The renal structural changes were not showed at 3
day in diabetic rats. Renal structural changes at 12
days post STZ treatment and this continued for 30
day post STZ tretament. These data indicate that STZ
treatment does not induce a direct effect. The main
structral changes in kidney of diabetic rats, include
proliferation of intraglomerular mesengial cell and here
and there PNL infiltration, intersititial nephritis and focal glomerulosclerosis (Fig. 6,7,8). In addition, it was
showed that capsular drops “Strongly Eozinophilic Deposits” were in Bowman capsule of kidney (Fig. 9).
Discussion
Diabetes mellitus is mainly a multisystemic disease
that it may cause many acute and chronically complications (1,2).
Brownlee and Serami reported that the metabolic
alterations and cellular disfunctions in diabetes mellitus
may be involved in the development of vascular disease (24). Diabetes is associated with alterations in

*P<0.05

Days
Urea
mg/dl
Creatinine
mg/dl
Sodium
meq/L
Potassium
meq/L
Calcium
mg/dl
Phosphor
mg/dl

3
52,1±2,53

Control
12
52,5±2,7

30
52,4±2,06

3
55,3±3,77

Diabetes Mellitus
12
30
100,1±7,14** 107,1±2,64**

1,05±0,11

1,15±0,11

1,15±015

1,2±0,21

2,4±0,58**

1,9±0,26**

142,3±2,6

142,6±1,9

141,8±2,3

143,6±1,76

145±1,34*

138,5±1,51*

5,41±0,47

5,7±0,31

6,12±0,32

5,57±0,53

6,5±0,56**

5,07±0,28**

9,88±0,21

9,86±0,28

9,91±0,32

8,88±0,89

10,92±0,30** 8,62±0,62**

6,03±0,55

6,08±0,46

5,58±0,47

6,76±0,52

7,31±1,17**

*P<0.05, **P<0.005
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3,85±0,38**

Table 6.

Some biochemical parameters
changes
in
control
and
STZ-induced diabetic rats 3-30
days. (Mann-Whitney U Test)

B.ÜSTÜNDAĞ et al.

Figure 8.
Figure 5.

Acini degradation, decrasing of number and damage of
Langerhans islet cells and polymorfonuclear infiltration in
pancreatic gland in STZ-induced diabetic rats at 3 day
(HE*200)

Figure 9.

Figure 6,

Figure 7.

The thickening of the glomerular basement membrane,
tubular dilatation and prolipheration of intraglomerular
mesengial cell in kidney in STZ-induced diabetic rats at
12 days (HE*200)

Interstitial nephritis and increasing of mononuclear fagosyt
in the kidney of STZ-induced diabetic rats at 30 days
(HE*200).

Focal glomerulosclerosis in the kidney of STZ-induced
diabetic rats at 30 days (HE*200).

The strongly eosinophilic deposits “Capsular Drops” in the
Bowman capsule and partially tubular necrosis in the kidney
of STZ-induced diabetic rats at 30 days (HE*400)

glomerular filtration rate, kidney mass and renal function which may elevate blood pressure through altering endogenous fluid and electrolyte balance (25).
RA system has long been konwn as a circulating hormonal system that controls blood pressure and electrolyte homeostasis. It is now known that components
of the RAS are also present in specific tissues, such as
the walls of blood vessel, and the heart, lung, liver,
kidney, brain, pituitary gland, ovary, testes, uterus,
chorion-amnion, placenta,gut and salivary glands. Angiotensin produced locally has an autocrine/paracrine
effect on angiotensin-mediated functions in these individual tissues (5,9,26).
In the STZ diabetes model that we chose, the
mechanisms of the acceptance of STZ resembles glucose and it is directly and selectively introduced into
B-cell (27,28).
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In our studies, serum glucose levels were 398±8,2
mg/dl at 3 day post STZ treatment and it were
490±11,75 mg/dl and 663±31 mg/dl at 12 and 30
days post STZ treatment.
Many pathologic changes occurred in pancreatic tissue in STZ-induced diabetic rats at 3 day. Main structural changes, include PNL infiltration, aciner degradation and langerhans islets damage and decrease and
decrease of number in STZ-induced diabetic rats.
These findings continued for 12 and 30 days post
STZ treatment.
Many investigators have reported increased serum
ACE activity and tissue ACE activity in diabetic humans. This increasing of ACE activity may be contribute to occurs the complications of diabetes mellitus
(14,29). ACE catalyzes the conversion of A I to A II.
Since diabetes increases serum ACE activity, serum A
II levels may be elevated resulting in a pressure response. Diabetes may produce increased A II levels due
to enhanced ACE activity. On other hand, levels may
remain unchanged if degradation of A II is increased
(16).
Serum ACE activity levels were measured sequence
65,4±0,85 U/L at 3 day, 101,2±2,63 U/L at 12 day
120,1±1,62 U/L at 30 days post STZ treatment in induced diabetic rats. We observed an increase satistically significantly in the serum ACE activity levels at 12
and 30 post STZ treatment in diabetic rats
(P<0.005), whereas no significant changes in the serum activity were found compared with to controls
(P>0.05).
Schartner et all. have reported increased serum
ACE activity in diabetic humans (30). Moreover, Funakawa et all. have reported that serum ACE activity
levels were elevated significantly compared with the
controls and it were related with hyertension and vascular complications (16). Erman et all. have reported
that serum ACE activity was significantly incerased in
the diabetic rats 14 days after induction of diabetes
and reduced insulin treatment (15,16,32).
The activity of ACE was found to be elevated in
DM rats as observed by Lieberman et al and the elevated levels of ACE activity in DM may come from
diffuse vascular damage as mentioned by Lieberman et
all. (14). Therefore it is excepted that depressed kallikrein generation may result in decrease release of the
renin, which is liberated from kininogen by kallikrein
and / or the liberated kinin may be rapidly inactived
by ACE in diabetes mellitus. These data are explain
high level of ACE activity in DM (14,33).
236

In our studies, we determined that the lung ACE
activity was showed a significantly increase in STZinduced diabetic rats at 12 day (P<0.05) and 30 days
(P<0.005) compared with the controls. Huskic et al
have reported that STZ induced-diabetes in the rats
cause significant increase in ACE activity was significantly elevated at 7 and 14 days post STZ treatmert in STZ-induced diabetic rats (15), but some
studies reported that the lung ACE activities were not
elevated in diabetic rats (16).
The liver ACE activity not changed in STZ induced
diabetic rats at 3 and 12 days post STZ treatment,
but it was significantly a rise diabetic rats at 30 days
(P<0.05). This increasing of ACE activity may be not
probably due elevated high glucose levels and diabetes.
Kohler and associate reported that renal renin levels in diabetic rats diminished prior the development
of hypertension (35). Recent studies reported that
ACE activity in the renal medulla was decreased but it
was sighificantly a rise of the ACE activity in renal
cortex in diabetic rats (18). In other study, Maeda et
all. have reported that ACE activities in the serum and
urine ACE were significantly elevated in diabetic rats
and treatment of diabetic rats with insulin to achieve
near euglysemia completely prevented these alterations
in ACE activity (36). In our studies, kidney ACE activity increased significantly at 12 days in diabetic rats
(P<0.05), whereas no significant changes in the activity were found compared with the control rats in induced diabetic rats at 12 and 30 days post STZ treatmert.
The blood electrolytes were decreased in STZ induced diabetic rats sodium and potassium levels were
significantly decreased in 12 and 30 days to compared
with the control groups in STZ induced diabetic rats
(10).
Specific pathologic lesions in kidney of STZinduced-diabetic rats occurred at 12 and 30 days,
whereas no significant pathologic changes in kidney of
STZ-induce diabetic rats were found in 3 days post
STZ treatment. Main structural changes in kidney
were focal glomerulosclerosis, increasing of glomerular
mesengial cells and interstitial fibrosis in STZ-induced
diabetic rats.
In this study, it is indicated that the diabetic nephropathyc changes observed in histopathologic examination such as the infiltration of PNLs and the proliferation of mesengial cells around the juxtaglomerular

B.ÜSTÜNDAĞ et al.

apparatus are the main reasons for the reduction in
renin and angiotensin production in this area. Therefore, ACE activity in the kidney, which was elevated at
12 days, may be indicative for the increased requirement of A II due to pathologic kidney changes
occurred in diabetes mellitus induced by STZ.

cause significant increase in ACE activity in serum and
lung at 12 and 30 days. On other hand, the kidney
changes due to occurred diabetes mellitus.
Further investigations should be required to clarify
the role of ACE activity of serum and variable tissue
(lung, liver and kidney) in diabetes mellitus.

The results showed that STZ-induced diabetes rats
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